Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment

Anxiety Clinical Trial

— Tele-CBT  

Official title:

Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05030285
• Other study ID #: HREC/17/QRBW/676
• Status: Recruiting
• Phase: N/A
• Start date: September 21, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: May 2022
• Source: The University of Queensland
• Contact: Nadeeka Dissanayaka, PhD
• Phone: 617 3346 6026
• Email: n.dissanayaka[@]uq.edu.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project will pilot a tailored Cognitive Behavioral Therapy (CBT) intervention delivered via telehealth videoconferencing (Tele-CBT) to reduce anxiety in people living with cognitive impairment. A process evaluation will inform its feasibility and implementation in the community nation-wide.

Description:

Anxiety is a pre-existing mental health issue in older persons with cognitive impairment (includes people with mild cognitive impairment (MCI) and dementia), with considerably high prevalence (14%) as compared to older persons in the general population (3%). Anxiety results in accelerated cognitive decline, increased aggressive behaviours, and even an increased risk of suicide. Anxiety also negatively influences quality of life (QoL) of the individual with cognitive impairment and their care partner, increases early institutionalisation, and amplifies economic burden.

The Tele-CBT package used in this study is a modification of existing manualised psychotherapeutic interventions for treatment of anxiety in people with Parkinson's disease and older adults with cognitive impairment. This new package incorporates techniques tailored to reduce anxiety in people with cognitive impairment, including symptom monitoring. The interventions will include various psychological techniques aimed at reducing anxiety and stress. The intervention consists of 6 weekly psychotherapy sessions. Each therapy session lasts between 30-60 minutes, depending on the participants' capacity to actively participate in session and on their cognitive functioning (e.g. complex attention, executive function). Support persons will be invited and instructed to actively engage in the therapy sessions as well as in between-session home tasks to support the person with cognitive impairment. These techniques will be facilitated via the use of non-immersive videos in telehealth videoconferencing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 26
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Persons with a diagnosis of mild cognitive impairment (MCI) or dementia of any aetiology based on a previous diagnosis by a clinician or scoring above threshold (=32; MCI =32 and dementia =27) for cognitive impairment in the Modified Telephone Interview for Cognitive Impairment (TICS-M).

• Persons screening positive for anxiety (scoring =9 in the Geriatric Anxiety Inventory, GAI) or reports subjective complaints of anxiety

Exclusion Criteria:

• Persons with severe dementia

• Persons who are unable to communicate or complete questionnaires

• Persons who are at high risk of suicide as identified by by the University of Queensland Suicidal Risk Assessment administered at the UQ Psychology clinic which has been modified for use by the Dementia and Neuro Mental Health Research Unit

• Persons who have major depression as the primary complaint without reported symptoms of anxiety.

• Persons on existing anxiolytics or antidepressants who have not been on a stable dose for at least 12 weeks before starting the trial and are unable to maintain the same dose for the duration of the trial. Changes to medication will be checked at each therapy and assessment session.

• Persons who are undergoing psychological therapy or will undergo psychological therapy over the trial duration.

Entry into the study:

Study entry will be determined by discussions with the core investigator team consisting of clinicians and experienced researchers.

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders
• Cognitive Dysfunction
• Cognitive Impairment
• Psychotherapy

Intervention

Behavioral:
• Cognitive Behavioral Therapy (CBT)
The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.

Locations

Country	Name	City	State
Australia	The University of Queensland	Brisbane	Queensland

Sponsors (1)

Lead Sponsor	Collaborator
The University of Queensland

Country where clinical trial is conducted

Australia, 

References & Publications (6)

Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Dec 18;4(3):509-16. doi: 10.1159/000357775. eCollection 2014 Sep-Dec. — View Citation

Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001 Spring;14(1):52-8. — View Citation

Konnopka A, König H. Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis. Pharmacoeconomics. 2020 Jan;38(1):25-37. doi: 10.1007/s40273-019-00849-7. — View Citation

Kuring JK, Mathias JL, Ward L. Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2018 Dec;28(4):393-416. doi: 10.1007/s11065-018-9396-2. Epub 2018 Dec 7. — View Citation

Poon E. A Systematic Review and Meta-Analysis of Dyadic Psychological Interventions for BPSD, Quality of Life and/or Caregiver Burden in Dementia or MCI. Clin Gerontol. 2019 Nov 22:1-21. doi: 10.1080/07317115.2019.1694117. [Epub ahead of print] — View Citation

Seyfried LS, Kales HC, Ignacio RV, Conwell Y, Valenstein M. Predictors of suicide in patients with dementia. Alzheimers Dement. 2011 Nov;7(6):567-73. doi: 10.1016/j.jalz.2011.01.006. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in anxiety	Change from baseline in anxiety as measured by the Rating Anxiety in Dementia Scale (RAID).	Post assessment (week 8). Scores ranging between 0 to 54 (lower score indicates better outcomes)
Secondary	Change in depression	Change from baseline in depression as measured by the Geriatric Depression Scale (GDS)	Post assessment (week 8). Scores ranging between 0 to 15 (lower score indicates better outcomes)
Secondary	Change in quality of life	Change from baseline in quality of life as measured by the Quality of Life in Alzheimer's Disease (QoL-AD)	Post assessment (week 8). Scores ranging between 0 to 52 (higher score indicates better outcomes)
Secondary	Change in carer burden	Change from baseline in carer burden as measured by the Zarit Burden Inventory (ZBI)	Post assessment (week 8). Scores ranging between 0-88 (lower score indicates better outcomes)